Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | The financial burden of cancer treatment and how to address it

Michael Hallek • 9 Jun 2016
EHA 2016
General

Michael Hallek, MD from the University of Cologne, Cologne, Germany talks about the issue of drug cost in oncology. According to Prof. Hallek, this is a political problem and an economic burden for society. He argues that politicans, companies, health insurers and patients need to work together proactively anf find a solution to make sure, that combination therapies are affordable everywhere in the world.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Michael Hallek

2:24
BCL-2 frontline therapy in CLL
Michael Hallek • 25 Aug 2020
3:53
Updates from the German CLL Study Group
Michael Hallek • 28 Aug 2020
3:02
Treating highly relapsed/refractory CLL
Michael Hallek • 27 Aug 2020
2:32
Value of MRD measurement in CLL
Michael Hallek • 27 Aug 2020

Related Videos

2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
1:12
The contribution of viral infections, such as EBV, to post-transplant lymphoproliferative disease
Susan Prockop • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals